Astellas Pharma Inc (4503):製薬・医療:M&Aディール及び事業提携情報

GlobalDataが発行した調査報告書(DATA904C11501)
◆英語タイトル:Astellas Pharma Inc (4503) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C11501
◆発行会社(リサーチ会社):GlobalData
◆発行日:2018年11月
◆ページ数:267
◆レポート形式:英語 / PDF
◆納品方法:Eメール
◆調査対象地域:日本
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規代理店です。同社発行の市場リサーチレポート及びリサーチサービスに関するお問い合わせは弊社までお願い致します。GlobalData社の概要及び新刊レポートはこちらでご確認いただけます。

【レポートの概要】

Summary
Astellas Pharma Inc (Astellas) is a research based pharmaceutical company that discovers, develops, manufactures, and commercializes a wide range of pharmaceuticals. The company’s product portfolio comprises both marketed products for the treatment of a wide range of urological diseases, infectious diseases, cancer, diseases and disorders of central nervous system (CNS), and metabolic diseases, immunodeficiency diseases, and transplantation. The company is investigating enfortumab vedotin in Phase 2 and Phase 3 clinical trials for the treatment of urothelial cancer; zolbetuximab in Phase 3 clinical trials for the treatment of gastric cancer and gastroesophageal junction cancer; roxadustat in Phase 3 clinical studies for the treatment of patients with anemia associated with chronic kidney disease (CKD) in patients on dialysis and non-dialysis; fezolinetant in Phase 2a clinical trials for the treatment of menopause-related vasomotor symptoms (MR-VMS) such as hot flashes and night sweats; and gilteritinib for the treatment of for acute myeloid leukemia (AML). It operates in the Americas; Europe; and Asia and Oceania through its network of subsidiaries and affiliates. Astellas is headquartered in Tokyo, Japan.

Astellas Pharma Inc (4503) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 8
List of Figures 11
Astellas Pharma Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 12
Astellas Pharma Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 13
Astellas Pharma Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 14
Astellas Pharma Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 15
Astellas Pharma Inc, Medical Devices Deals, 2012 to YTD 2018 17
Astellas Pharma Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 18
Astellas Pharma Inc, Pharmaceuticals & Healthcare, Deal Details 31
Venture Financing 31
Coda Biotherapeutics Raises USD19 Million in Series A Financing 31
Twentyeight-Seven Therapeutics Raises USD65 Million in Series A Venture Financing 32
eFFECTOR Therapeutics Raises USD38.6 Million in Series C Financing 34
Bicycle Therapeutics Raises USD51.35 Million in Series B Round of Financing 36
Oncorus Raises Additional USD4 Million in Series A Financing 38
Cleave Biosciences Raises USD37 Million in Series B Financing Round 39
Tizona Therapeutics Raises USD43 Million in Series B Financing 41
Tizona Therapeutics Secures USD27 Million in Series A Funding Round 43
Effector Therapeutics Raises USD40 Million in Series B Venture Financing 44
Euroscreen Raises USD17.8 Million in Series B Financing Round 46
Quethera Raises Funds in Seed Financing Round 48
Ocata Therapeutics Secures USD6 Million from Silicon Valley Bank 49
Kanyos Bio Raises USD16 Million in Venture Financing 50
Potenza Therapeutics Raises USD38 Million in Series A Venture Financing 51
Crescendo Biologics Raises Funds through Venture Financing 52
Innocrin Pharma Raises Funds through Venture Financing 53
Viamet Pharma Raises USD60 Million in Series D Venture Financing 54
Bicycle Therapeutics Raises USD32 Million in Series A Venture Financing 55
Raze Therapeutics Raises USD24 Million in Series A Venture Financing 56
Crescendo Biologics Raises US$28 Million In Series A Financing 58
Seldar Pharma Raises US$13 Million In Venture Financing 60
Ganymed Pharmaceuticals Secures USD60.74 Million in Venture Funding 61
Universal Cells Raises USD0.06 Million in Venture Financing 62
Ganymed Pharma Raises US$60.7 Million In Series E Financing 63
Mitokyne Raises US$45 Million In Series A Financing 64
Effector Therapeutics Raises US$45 Million In Series A Financing 65
Tacurion Pharma To Raise US$15 Million In Venture Financing 67
Cleave Biosciences Raises US$54 Million In Series A Financing 68
DecImmune Therapeutics Raises US$2.2 Million In Financing Round 70
Bicycle Therapeutics Raises US$6 Million In Venture Financing 71
Euroscreen Raises US$13 Million In Series A Financing 73
F2G Raises US$30 Million In Venture Financing 74
PhaseBio Pharma Raises Additional US$23 Million In The Third Tranche Of Series B Financing Round 75
Telsar Pharma Raises US$14 Million In Series A Financing 77
Partnerships 78
Anaeropharma Science Enters into Research Agreement with Astellas Pharma 78
Actinium Pharma Enters into Research and Option Agreement with Astellas Pharma 79
ClearPath Vaccines and Astellas Pharma Enter into Research Agreement with Boston Children’s Hospital 80
Astellas Pharma, Institute of Medical Science, Chiba University and Asahi Kogyosha Enter into Research Agreement 81
Astellas Pharma Enters into Co-Promotion Agreement with MSD 82
Astellas Pharma Enters into Agreement with Medicines for Malaria Venture 83
Astellas Pharma Enters into Agreement with TB Alliance 84
Astellas Pharma and Toa Eiyo Enter into Co-Promotion Agreement 85
Astellas Pharma Amends Agreement with Pfizer 86
Astellas Pharma Enters into Agreement with Institute of Medical Science, the University of Tokyo 87
Ribomic Enters into Research Agreement with Astellas Pharma 88
X-Chem Enters into Agreement with Astellas Pharma 89
Astellas Pharma Enters into Distribution Agreement with Kyowa Pharma 90
Astellas Pharma Enters into Research Agreement with GenomeDx Biosciences 91
Astellas Pharma Enters into Research Agreement with Quebec Urological Association Foundation 92
Courtagen Life Sciences Enters into Agreement with Astellas Pharma 93
IMSUT and Astellas Pharma Enter into Agreement 94
Excelra Knowledge Solutions Enters into Agreement with Astellas Pharma 95
Astellas Pharm, Kyowa Hakko Kirin, Daiichi Sankyo, Eisai, Ono Pharma and Chugai Pharma to Enter into Agreemet with Four Research Institutions 96
Astellas Pharma, Daiichi Sankyo and Takeda Pharma Enter into Research Agreement 98
Transplant Genomics Enters into Clinical Trial Agreement with Astellas Pharma 99
Astellas Pharma Enters into Research Agreement with National Institute of Advanced Industrial Science and Technology 100
NuMedii Enters into Agreement with Astellas Pharma 101
Biovista Enters into Drug Collaboration Agreement with Astellas Pharma 102
Astellas Pharma Forms Joint Venture with ClearPath Development 103
Astellas Pharma Forms Joint Venture with Anokion 104
Cyclenium Pharma Enters into Discovery Agreement with Astellas Pharma 105
InVivoScribe Enters into Agreement with Astellas Pharma 106
Astellas Pharma Enters into R&D Agreement with Potenza Therapeutics 107
Ventana Medical Enters into Agreement with Astellas Pharma to Develop Novel Automated Tissue Diagnostics 108
Astellas Pharma Enters into Option Agreement with MD Anderson 109
Immuno-Biological Labs Enters Into Research Agreement With Astellas Pharma 110
ROVI Enters into Agreement with Astellas to Market Volutsa 111
Proteostasis Therapeutics Amends Research Agreement with Astellas Pharma 112
Dana-Farber Cancer Institute Enters into Research Agreement with Astellas Pharma 113
Astellas Pharma Enters into Research Agreement with Harvard Medical School 114
Daewoong Pharma and Astellas Pharma Korea Enter into Agreement 115
Cancer Research and Cancer Research Technology Enter into Co-Development Agreement with Astellas Pharma 116
Astellas Pharma Forms Joint Venture With ClearPath Development 117
Astellas Pharma Enters into Research Agreement with Immuno-Biological Labs 118
Astellas Pharma Enters Into R&D Agreement With Mitokyne For Drug Discovery 119
Amgen and Astellas Pharma Form Joint Venture 120
Astellas Pharma Enters Into Co-Promotion Agreement With MSD For Ipragliflozin 121
Seattle Genetics Exercises Option For Co-Development Agreement With Agensys For ASG-15ME 122
Astellas Pharma US Enters Into Distribution Agreement With Tecnofarma For Enzalutamide 123
Amgen Enters Into Co-Development Agreement With Astellas 124
Astellas Pharma Enters Into Co-Development Agreement With Ambrx 125
University of Tokyo Enters Into Research Agreement With Astellas Pharma To Discover New Drugs For NTDs 126
Nagasaki University Enters Into Research Agreement With Astellas Pharma To Discover New Drugs For NTDs 127
Astellas Pharma Enters Into Drug Discovery Agreement With AIST 128
KEK Enters Into Research Agreement With Astellas Pharma To Discover Drugs For Infectious Diseases 129
Astellas Pharma Global Development Enters Into Co-Development Agreement With Abbott Labs For Cytomegalovirus Vaccine Trial 130
Tokyo Institute of Technology Enters Into Research Agreement With Astellas Pharma 131
TI Pharma, Astellas Pharma And Merck Enter Into Co-Development Agreement With Swiss Tropical and Public Health 132
Astellas Pharma Enters Into Co-Development Agreement With DNDi For Neglected Diseases 134
Kaketsuken Enters Into Co-Marketing Agreement With Astellas Pharma For Polio Vaccine 135
Pfizer Extends Co-Promotion Agreement With Astellas Pharma For Lipitor 136
National Comprehensive Cancer Enters Into Co-Development Agreement With AVEO Pharma And Astellas Pharma 137
Astellas Pharma Enters Into Distribution Agreement With Sanwa Kagaku Kenkyusho 139
Astellas Pharma Enters Into Co-Development Agreement With UCB For Cimzia 140
Licensing Agreements 142
Astellas Pharma to Enter into Option Agreement with Gene Therapy Research Institution 142
Astellas Pharma Enters into Licensing Agreement with Aquinox Pharma 143
Cardurion Pharma Enters into Licensing Agreement with Astellas Pharma 144
Astellas Pharma Enters into Licensing Agreement with Tottori University 145
Astellas Institute for Regenerative Medicine Enters into Licensing Agreement with Universal Cells 146
BlueRock Therapeutics Enters into Licensing Agreement with Universal Cells 147
Mitobridge Enters into Licensing Agreement with Ecole Polytechnique Federale de Lausanne 148
Astellas Pharma Enters into Licensing Agreement with Affinivax 149
Astellas Pharma Enters into Licensing Agreement with Auration Biotech 150
Maruho Enters into Licensing Agreement with Astellas Pharma 151
Bellicum Pharma Enters into Licensing Agreement with Agensys 152
Adaptimmune Therapeutics Enters into Licensing Agreement with Universal Cells 153
Astellas Pharma Enters into Licensing Agreement with Chromocell 154
Vical Enters into Licensing Agreement with Astellas Pharma for ASP2397 155
Mitobridge Enters into Licensing Agreement with Salk Institute for Biological Studies 157
Astellas Pharma Enters into Licensing Agreement with Immunomic Therapeutics 158
Euroscreen Enters into Licensing Agreement with Merck 159
EMERpharma Enters into Option Agreement with Astellas Pharma to License ASP2905 160
Cytokinetics Enters Into Licensing Agreement With Astellas Pharma For CK-2127107 161
Astellas Pharma Expands Licensing Agreement with Cytokinetics 163
Astellas Pharma And Drais Pharma Enter Into Licensing Agreement To Develop ASP7035 165
Cubist Pharma Enters Into Licensing Agreement With Astellas Pharma For Ceftolozane 166
Maruho Enters into Licensing Agreement with Astellas Pharma 168
Optimer Pharma Enters Into Licensing Agreement With Astellas Pharma For Fidaxomicin 169
Astellas Research Institute of America Enters into License Agreement with biOasis Technologies 171
Astellas Pharma Enters into Licensing Agreement with Clino 172
Ocata Therapeutics Enters into Licensing Agreement with Allele Biotech 173
Agensys Enters into Licensing Agreement with Sea Lane Biotech 174
Equity Offering 175
Anokion to Raise USD16 Million in Private Placement of Shares 175
Cytokinetics Raises USD10 Million in Private Placement of Shares 176
Ocata Therapeutics Prices Public Offering of Shares and Warrants for USD30 Million 177
Advanced Cell to Raise USD30 Million in Private Placement of Shares 179
Advanced Cell Technology Files Registration Statement For Public Offering Of Securities For US$35 Million 180
Advanced Cell Technology Completes First Tranche Of Private Placement Of Shares For US$1 Million 181
Asset Transactions 182
Astellas Pharma May Sell its Central and Eastern Europe Assets 182
Kite Pharma Acquires Agensys Research Facilities from Astellas Pharma 183
LTL Pharma Acquires 16 Long-Listed Products in Japan from Astellas Pharma for USD182 Million 184
Grunenthal to Acquire Qutenza from Astellas Pharma Europe 185
Thunderbolt Pharma Acquires Rights to BAFF/APRIL Dual Antagonist Program from Astellas Pharma 186
LEO Pharma Acquires Global Dermatology Portfolio of Astellas Pharma for USD724 Million 187
MicroBiopharm Japan Acquires Kiyosu Plant from Astellas Pharma 188
Nichi-Iko Pharma Acquires Pharmaceutical Manufacturing Business from Astellas Pharma Tech 189
Cumberland Pharma Acquires Vaprisol From Astellas Pharma 190
Taiho Pharma Acquires Fermentation Research-Related Assets from Astellas Pharma 191
Seldar Pharma Acquires ASP7147 Compound From Astellas Pharma 192
Telsar Pharma To Acquire ASP3291 Compound Of Astellas Pharma 193
Acquisition 194
Astellas Pharma Acquires Quethera 194
Astellas Pharma Acquires Universal Cells 195
Astellas Pharma Acquires Mitobridge 196
Astellas Pharma Acquires Ogeda for up to USD852 Million 197
Astellas Pharma Acquires Ganymed Pharma 198
Avara Pharma Acquires Astellas Pharma Technologies from Astellas US Holding 200
Astellas Pharma Acquires Ocata Therapeutics for up to USD384 Million in Tender Offer 201
Gilead Sciences Acquires EpiTherapeutics for USD65 Million 203
GlaxoSmithKline Acquires Remaining 80.02% Stake In Cellzome, Proteomics Company, For US$99 Million 204
Astellas Pharma Inc – Key Competitors 206
Astellas Pharma Inc – Key Employees 207
Astellas Pharma Inc – Locations And Subsidiaries 210
Head Office 210
Other Locations & Subsidiaries 210
Joint Venture 216
Recent Developments 217
Strategy And Business Planning 217
Nov 20, 2018: Astellas Global Health Foundation launches – Foundation to support improving access to health for underserved populations 217
Oct 31, 2018: Astellas announces construction of new research, development and manufacturing facilities for drugs using innovative modalities/technologies including antibodies and cell therapies 218
Financial Announcements 219
Oct 31, 2018: Astellas announce financial results of for the first six months of FY2018 219
Apr 26, 2018: Astellas Reports Financial Results for FY2017 223
Jan 31, 2018: Astellas Reports Financial Results for the First Nine Months of FY2017 225
Oct 31, 2017: Astellas Reports First Half FY2017 Financial Results, Revises Fiscal Year Outlook 227
Jul 28, 2017: Astellas Reports First Quarter FY2017 Financial Results 229
Apr 27, 2017: Astellas Reports Full Year FY2016 Financial Results 231
Jan 31, 2017: Astellas Reports the First Nine Months Financial Results of FY2016 233
Corporate Communications 234
Nov 12, 2018: Astellas names Eloiza Domingo-Snyder to Head of Diversity and Inclusion 234
Sep 18, 2018: Astellas Promotes Geoff Towle to Vice President of Oncology Marketing at Astellas US 235
Aug 23, 2018: Astellas announces promotion of Rodrigo Fernandez to Vice President, Latin America 236
May 15, 2018: Astellas Names Bernhardt Zeiher As New Chief Medical Officer 237
Mar 15, 2018: Astellas Names Percival Barretto-Ko President, Americas Operations 238
Mar 13, 2018: Astellas Announces Key Leadership Changes in Legal, Human Resources 239
Jan 31, 2018: Astellas Appoints Kenji Yasukawa as President and CEO 240
Jun 20, 2017: The Astellas Oncology C3 Prize Competition Returns for a Second Year; Aims to Inspire and Support Innovative Ideas for Cancer Care with $100,000 in Grants 241
Apr 28, 2017: Astellas Announces Key Leadership Promotions in Development Organization 242
Feb 08, 2017: Astellas Announces Changes in Management Structure and Global Function 243
Feb 08, 2017: Astellas Announces Personnel Changes and Organizational Changes 244
Government and Public Interest 246
May 31, 2018: Astellas Oncology C3 Prize Returns for Third Year with Focus on Improving Cancer Care in Underserved Regions of the World 246
Feb 02, 2018: BCRF Announces Expansion of the Drug Research Collaborative 247
Nov 23, 2017: Innovative Medicines Canada and Astellas Announce Grant to the University Health Network’s Transplant Innovation Fund 248
Oct 31, 2017: GHIT Fund Accelerates Promising Efforts to Find New Treatments, Vaccines and Diagnostics for Malaria, Tuberculosis, Leishmaniasis and Mycetoma 249
Jul 05, 2017: Astellas Named to FTSE4Good Sustainability Index for the Sixth Consecutive Year 252
Jun 05, 2017: Kyoto University and Astellas Inaugurate “Alliance Station” with Aim of Realizing Advanced Medical Treatments 253
May 23, 2017: Action On Fistula To Transform 4,500 Lives By 2020 254
Jan 18, 2017: Astellas Announces Participation in Access Accelerated Builds on Company Commitment to improve Access to Health 256
Product News 257
Oct 31, 2017: Proteostasis Therapeutics Focuses on Research and Development of CF Drug Candidates and Astellas Pharma Collaboration Programs 257
Oct 11, 2017: Astellas, Mitsubishi Tanabe Pharma, and Daiichi Sankyo Conduct “JOINUS,” a New Drug Discovery Program Using Drug-Repositioning Compound Library 258
Feb 02, 2018: The Breast Cancer Research Foundation Announces the Expansion of the Drug Research Collaborative to Better Understand Potential Treatment Pathways for Breast Cancer Patients 259
Clinical Trials 260
Aug 31, 2017: Astellas to Present New Data for IMAB362 at 2017 European Society of Medical Oncology Annual Meeting 260
Other Significant Developments 261
Oct 09, 2018: Astellas details progress and commitment to patients and the community in the company’s americas 2017 corporate social responsibility report card 261
Oct 09, 2018: Astellas, Mitsubishi Tanabe Pharma, and Daiichi Sankyo announce second public recruitment offering of “Joinus”, a joint research program to discover new drugs using drug-repositioning compound library 262
Feb 05, 2018: Astellas Announces Changes in Management Structure, Global Function, and Top Management Committees 263
Feb 05, 2018: Astellas Announces Organizational Changes 264
Jul 26, 2017: Astellas Announces Wind-Down of Agensys Research Operations 265
May 31, 2017: Astellas Announces New Global Website Launch 266
Appendix 267
Methodology 267
About GlobalData 267
Contact Us 267
Disclaimer 267

List of Tables
Astellas Pharma Inc, Pharmaceuticals & Healthcare, Key Facts, 2018 2
Astellas Pharma Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 12
Astellas Pharma Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 13
Astellas Pharma Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 14
Astellas Pharma Inc, Deals By Therapy Area, 2012 to YTD 2018 15
Astellas Pharma Inc, Medical Devices Deals, 2012 to YTD 2018 17
Astellas Pharma Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 18
Coda Biotherapeutics Raises USD19 Million in Series A Financing 31
Twentyeight-Seven Therapeutics Raises USD65 Million in Series A Venture Financing 32
eFFECTOR Therapeutics Raises USD38.6 Million in Series C Financing 34
Bicycle Therapeutics Raises USD51.35 Million in Series B Round of Financing 36
Oncorus Raises Additional USD4 Million in Series A Financing 38
Cleave Biosciences Raises USD37 Million in Series B Financing Round 39
Tizona Therapeutics Raises USD43 Million in Series B Financing 41
Tizona Therapeutics Secures USD27 Million in Series A Funding Round 43
Effector Therapeutics Raises USD40 Million in Series B Venture Financing 44
Euroscreen Raises USD17.8 Million in Series B Financing Round 46
Quethera Raises Funds in Seed Financing Round 48
Ocata Therapeutics Secures USD6 Million from Silicon Valley Bank 49
Kanyos Bio Raises USD16 Million in Venture Financing 50
Potenza Therapeutics Raises USD38 Million in Series A Venture Financing 51
Crescendo Biologics Raises Funds through Venture Financing 52
Innocrin Pharma Raises Funds through Venture Financing 53
Viamet Pharma Raises USD60 Million in Series D Venture Financing 54
Bicycle Therapeutics Raises USD32 Million in Series A Venture Financing 55
Raze Therapeutics Raises USD24 Million in Series A Venture Financing 56
Crescendo Biologics Raises US$28 Million In Series A Financing 58
Seldar Pharma Raises US$13 Million In Venture Financing 60
Ganymed Pharmaceuticals Secures USD60.74 Million in Venture Funding 61
Universal Cells Raises USD0.06 Million in Venture Financing 62
Ganymed Pharma Raises US$60.7 Million In Series E Financing 63
Mitokyne Raises US$45 Million In Series A Financing 64
Effector Therapeutics Raises US$45 Million In Series A Financing 65
Tacurion Pharma To Raise US$15 Million In Venture Financing 67
Cleave Biosciences Raises US$54 Million In Series A Financing 68
DecImmune Therapeutics Raises US$2.2 Million In Financing Round 70
Bicycle Therapeutics Raises US$6 Million In Venture Financing 71
Euroscreen Raises US$13 Million In Series A Financing 73
F2G Raises US$30 Million In Venture Financing 74
PhaseBio Pharma Raises Additional US$23 Million In The Third Tranche Of Series B Financing Round 75
Telsar Pharma Raises US$14 Million In Series A Financing 77
Anaeropharma Science Enters into Research Agreement with Astellas Pharma 78
Actinium Pharma Enters into Research and Option Agreement with Astellas Pharma 79
ClearPath Vaccines and Astellas Pharma Enter into Research Agreement with Boston Children's Hospital 80
Astellas Pharma, Institute of Medical Science, Chiba University and Asahi Kogyosha Enter into Research Agreement 81
Astellas Pharma Enters into Co-Promotion Agreement with MSD 82
Astellas Pharma Enters into Agreement with Medicines for Malaria Venture 83
Astellas Pharma Enters into Agreement with TB Alliance 84
Astellas Pharma and Toa Eiyo Enter into Co-Promotion Agreement 85
Astellas Pharma Amends Agreement with Pfizer 86
Astellas Pharma Enters into Agreement with Institute of Medical Science, the University of Tokyo 87
Ribomic Enters into Research Agreement with Astellas Pharma 88
X-Chem Enters into Agreement with Astellas Pharma 89
Astellas Pharma Enters into Distribution Agreement with Kyowa Pharma 90
Astellas Pharma Enters into Research Agreement with GenomeDx Biosciences 91
Astellas Pharma Enters into Research Agreement with Quebec Urological Association Foundation 92
Courtagen Life Sciences Enters into Agreement with Astellas Pharma 93
IMSUT and Astellas Pharma Enter into Agreement 94
Excelra Knowledge Solutions Enters into Agreement with Astellas Pharma 95
Astellas Pharm, Kyowa Hakko Kirin, Daiichi Sankyo, Eisai, Ono Pharma and Chugai Pharma to Enter into Agreemet with Four Research Institutions 96
Astellas Pharma, Daiichi Sankyo and Takeda Pharma Enter into Research Agreement 98
Transplant Genomics Enters into Clinical Trial Agreement with Astellas Pharma 99
Astellas Pharma Enters into Research Agreement with National Institute of Advanced Industrial Science and Technology 100
NuMedii Enters into Agreement with Astellas Pharma 101
Biovista Enters into Drug Collaboration Agreement with Astellas Pharma 102
Astellas Pharma Forms Joint Venture with ClearPath Development 103
Astellas Pharma Forms Joint Venture with Anokion 104
Cyclenium Pharma Enters into Discovery Agreement with Astellas Pharma 105
InVivoScribe Enters into Agreement with Astellas Pharma 106
Astellas Pharma Enters into R&D Agreement with Potenza Therapeutics 107
Ventana Medical Enters into Agreement with Astellas Pharma to Develop Novel Automated Tissue Diagnostics 108
Astellas Pharma Enters into Option Agreement with MD Anderson 109
Immuno-Biological Labs Enters Into Research Agreement With Astellas Pharma 110
ROVI Enters into Agreement with Astellas to Market Volutsa 111
Proteostasis Therapeutics Amends Research Agreement with Astellas Pharma 112
Dana-Farber Cancer Institute Enters into Research Agreement with Astellas Pharma 113
Astellas Pharma Enters into Research Agreement with Harvard Medical School 114
Daewoong Pharma and Astellas Pharma Korea Enter into Agreement 115
Cancer Research and Cancer Research Technology Enter into Co-Development Agreement with Astellas Pharma 116
Astellas Pharma Forms Joint Venture With ClearPath Development 117
Astellas Pharma Enters into Research Agreement with Immuno-Biological Labs 118
Astellas Pharma Enters Into R&D Agreement With Mitokyne For Drug Discovery 119
Amgen and Astellas Pharma Form Joint Venture 120
Astellas Pharma Enters Into Co-Promotion Agreement With MSD For Ipragliflozin 121
Seattle Genetics Exercises Option For Co-Development Agreement With Agensys For ASG-15ME 122
Astellas Pharma US Enters Into Distribution Agreement With Tecnofarma For Enzalutamide 123
Amgen Enters Into Co-Development Agreement With Astellas 124
Astellas Pharma Enters Into Co-Development Agreement With Ambrx 125
University of Tokyo Enters Into Research Agreement With Astellas Pharma To Discover New Drugs For NTDs 126
Nagasaki University Enters Into Research Agreement With Astellas Pharma To Discover New Drugs For NTDs 127
Astellas Pharma Enters Into Drug Discovery Agreement With AIST 128
KEK Enters Into Research Agreement With Astellas Pharma To Discover Drugs For Infectious Diseases 129
Astellas Pharma Global Development Enters Into Co-Development Agreement With Abbott Labs For Cytomegalovirus Vaccine Trial 130
Tokyo Institute of Technology Enters Into Research Agreement With Astellas Pharma 131
TI Pharma, Astellas Pharma And Merck Enter Into Co-Development Agreement With Swiss Tropical and Public Health 132
Astellas Pharma Enters Into Co-Development Agreement With DNDi For Neglected Diseases 134
Kaketsuken Enters Into Co-Marketing Agreement With Astellas Pharma For Polio Vaccine 135
Pfizer Extends Co-Promotion Agreement With Astellas Pharma For Lipitor 136
National Comprehensive Cancer Enters Into Co-Development Agreement With AVEO Pharma And Astellas Pharma 137
Astellas Pharma Enters Into Distribution Agreement With Sanwa Kagaku Kenkyusho 139
Astellas Pharma Enters Into Co-Development Agreement With UCB For Cimzia 140
Astellas Pharma to Enter into Option Agreement with Gene Therapy Research Institution 142
Astellas Pharma Enters into Licensing Agreement with Aquinox Pharma 143
Cardurion Pharma Enters into Licensing Agreement with Astellas Pharma 144
Astellas Pharma Enters into Licensing Agreement with Tottori University 145
Astellas Institute for Regenerative Medicine Enters into Licensing Agreement with Universal Cells 146
BlueRock Therapeutics Enters into Licensing Agreement with Universal Cells 147
Mitobridge Enters into Licensing Agreement with Ecole Polytechnique Federale de Lausanne 148
Astellas Pharma Enters into Licensing Agreement with Affinivax 149
Astellas Pharma Enters into Licensing Agreement with Auration Biotech 150
Maruho Enters into Licensing Agreement with Astellas Pharma 151
Bellicum Pharma Enters into Licensing Agreement with Agensys 152
Adaptimmune Therapeutics Enters into Licensing Agreement with Universal Cells 153
Astellas Pharma Enters into Licensing Agreement with Chromocell 154
Vical Enters into Licensing Agreement with Astellas Pharma for ASP2397 155
Mitobridge Enters into Licensing Agreement with Salk Institute for Biological Studies 157
Astellas Pharma Enters into Licensing Agreement with Immunomic Therapeutics 158
Euroscreen Enters into Licensing Agreement with Merck 159
EMERpharma Enters into Option Agreement with Astellas Pharma to License ASP2905 160
Cytokinetics Enters Into Licensing Agreement With Astellas Pharma For CK-2127107 161
Astellas Pharma Expands Licensing Agreement with Cytokinetics 163
Astellas Pharma And Drais Pharma Enter Into Licensing Agreement To Develop ASP7035 165
Cubist Pharma Enters Into Licensing Agreement With Astellas Pharma For Ceftolozane 166
Maruho Enters into Licensing Agreement with Astellas Pharma 168
Optimer Pharma Enters Into Licensing Agreement With Astellas Pharma For Fidaxomicin 169
Astellas Research Institute of America Enters into License Agreement with biOasis Technologies 171
Astellas Pharma Enters into Licensing Agreement with Clino 172
Ocata Therapeutics Enters into Licensing Agreement with Allele Biotech 173
Agensys Enters into Licensing Agreement with Sea Lane Biotech 174
Anokion to Raise USD16 Million in Private Placement of Shares 175
Cytokinetics Raises USD10 Million in Private Placement of Shares 176
Ocata Therapeutics Prices Public Offering of Shares and Warrants for USD30 Million 177
Advanced Cell to Raise USD30 Million in Private Placement of Shares 179
Advanced Cell Technology Files Registration Statement For Public Offering Of Securities For US$35 Million 180
Advanced Cell Technology Completes First Tranche Of Private Placement Of Shares For US$1 Million 181
Astellas Pharma May Sell its Central and Eastern Europe Assets 182
Kite Pharma Acquires Agensys Research Facilities from Astellas Pharma 183
LTL Pharma Acquires 16 Long-Listed Products in Japan from Astellas Pharma for USD182 Million 184
Grunenthal to Acquire Qutenza from Astellas Pharma Europe 185
Thunderbolt Pharma Acquires Rights to BAFF/APRIL Dual Antagonist Program from Astellas Pharma 186
LEO Pharma Acquires Global Dermatology Portfolio of Astellas Pharma for USD724 Million 187
MicroBiopharm Japan Acquires Kiyosu Plant from Astellas Pharma 188
Nichi-Iko Pharma Acquires Pharmaceutical Manufacturing Business from Astellas Pharma Tech 189
Cumberland Pharma Acquires Vaprisol From Astellas Pharma 190
Taiho Pharma Acquires Fermentation Research-Related Assets from Astellas Pharma 191
Seldar Pharma Acquires ASP7147 Compound From Astellas Pharma 192
Telsar Pharma To Acquire ASP3291 Compound Of Astellas Pharma 193
Astellas Pharma Acquires Quethera 194
Astellas Pharma Acquires Universal Cells 195
Astellas Pharma Acquires Mitobridge 196
Astellas Pharma Acquires Ogeda for up to USD852 Million 197
Astellas Pharma Acquires Ganymed Pharma 198
Avara Pharma Acquires Astellas Pharma Technologies from Astellas US Holding 200
Astellas Pharma Acquires Ocata Therapeutics for up to USD384 Million in Tender Offer 201
Gilead Sciences Acquires EpiTherapeutics for USD65 Million 203
GlaxoSmithKline Acquires Remaining 80.02% Stake In Cellzome, Proteomics Company, For US$99 Million 204
Astellas Pharma Inc, Key Competitors 206
Astellas Pharma Inc, Key Employees 207
Astellas Pharma Inc, Other Locations 210
Astellas Pharma Inc, Subsidiaries 210
Astellas Pharma Inc, Joint Venture 216

List of Figures
Astellas Pharma Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Astellas Pharma Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Astellas Pharma Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Astellas Pharma Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Astellas Pharma Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 12
Astellas Pharma Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 13
Astellas Pharma Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 14
Astellas Pharma Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 15
Astellas Pharma Inc, Medical Devices Deals, 2012 to YTD 2018 17

【免責事項】
http://www.globalresearch.jp/disclaimer

★リサーチレポート[ Astellas Pharma Inc (4503):製薬・医療:M&Aディール及び事業提携情報(Astellas Pharma Inc (4503) - Pharmaceuticals & Healthcare - Deals and Alliances Profile)]についてメールでお問い合わせはこちらでお願いします。

◆H&Iグローバルリサーチのお客様(例)◆